# Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

> **NCT01140997** · PHASE2 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 211 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Ypeginterferon alfa-2b
- **DRUG:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT01140997
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-01
- **Final completion:** 2012-03
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2013-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01140997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01140997, "Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01140997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*